Despite the role of ABC proteins in determining drug resistance in hematologic and solid cancers, it is still a matter of controversy, and many studies in the past decades have shown a relationship between ABCG2 overexpression and poor clinical outcome in AML. This evidence concerns the gene ABCG2 and acute myeloid leukemia.